Andere Kunden interessierten sich auch für
![Nissl Body]( "Nissl Body")
Nissl Body25,99 €![Radiation Induced Cognitive Decline]( "Radiation Induced Cognitive Decline")
Radiation Induced Cognitive Decline22,99 €![Hippocampus]( "Hippocampus")
Hippocampus22,99 €![Perinatal hypoxic-ischaemic encephalopathy - twenty years after]( "Perinatal hypoxic-ischaemic encephalopathy - twenty years after")
Perinatal hypoxic-ischaemic encephalopathy - twenty years after18,99 €![Memory complaints: Diagnostic guide]( "Memory complaints: Diagnostic guide")
Memory complaints: Diagnostic guide39,99 €![Assessment of the protective effect of KN-93 and RA in epilepsy]( "Assessment of the protective effect of KN-93 and RA in epilepsy")
Assessment of the protective effect of KN-93 and RA in epilepsy26,99 €![Characterization of Hippocampus Using Textural Analysis in Epileptics]( "Characterization of Hippocampus Using Textural Analysis in Epileptics")
Characterization of Hippocampus Using Textural Analysis in Epileptics32,99 €
High Quality Content by WIKIPEDIA articles! Xaliproden (codenamed SR57746) is a drug which acts as a 5HT1A agonist. It has neurotrophic and neuroprotective effects in vitro, and has been proposed for use in the treatment of several neurodegenerative conditions including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Development of xaliproden for these two indications was discontinued in 2007 following analysis of Phase III data. While the drug did show an effect on hippocampal volume (suggesting perhaps a slowing of cell loss), there was insufficient evidence for efficacy in counteracting Alzheimer's related cognitive decline.